Journal article

Physical comorbidities in men with mood and anxiety disorders: A population-based study

L Sanna, AL Stuart, JA Pasco, MA Kotowicz, M Berk, P Girardi, SL Brennan, LJ Williams

BMC Medicine | BMC | Published : 2013

Open access

Abstract

Background: The mind-body nexus has been a topic of growing interest. Further data are however required to understand the specific relationship between mood and anxiety disorders and individual physical health conditions, and to verify whether these psychiatric disorders are linked to overall medical burden.Methods: This study examined data collected from 942 men, 20 to 97 years old, participating in the Geelong Osteoporosis Study. A lifetime history of mood and anxiety disorders was identified using the Structured Clinical Interview for DSM-IV-TR Research Version, Non-patient edition (SCID-I/NP). The presence of medical conditions (lifetime) was self-reported and confirmed by medical record..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

Livia Sanna, Amanda L Stuart, Mark A Kotowicz, and Sharon L Brennan have no conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript. Paolo Girardi has in the past three years received research support from Lilly and Janssen, participated in advisory boards for Lilly, Organon, Pfizer, and Schering, and received honoraria from Lilly and Organon. Julie A Pasco has received speaker fees from Amgen, Eli Lilly and Sanofi-Aventis and funding from the Geelong Region Medical Research Foundation, Barwon Health, Perpetual Trustees, the Dairy Research and Development Corporation, The University of Melbourne, the Ronald Geoffrey Arnott Foundation, ANZ Charitable Trust, the American Society for Bone and Mineral Research, Amgen (Europe) GmBH and the NHMRC. Michael Berk has received Grant/Research Support from the NIH, Simons Foundation, CRC for Mental Health, Stanley Medical Research Institute, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Pfizer and a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay and Wyeth. Lana J Williams has received Grant/Research support from Eli Lilly, Pfizer, The University of Melbourne, Deakin University and the NHMRC.The study was funded by the National Health and Medical Research Council (NHMRC) of Australia. Sharon L Brennan is supported by a NHMRC Early Career Fellowship (1012472). The funding providers played no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; or in preparation, review, or approval of the manuscript. The authors acknowledge the men who participated in the study.